

application 101 02 977.2 as filed on January 23, 2001. The disclosures of the PCT/DK02/00038 and 101 02 977.2 applications are incorporated by reference.--

On page 24, after the last line, kindly add the following:

-- The invention has been described in detail with reference to preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements within the spirit and scope of the invention. All references disclosed herein are incorporated by reference.--

After page 72, on a new page, please add the following Abstract:

--The present invention relates to a test system for the identification and testing of active compounds which act on synaptic transmission (active compounds for treatment of neuronal diseases), which influence endo/exocytosis, which influence processing of proteins and in particular of active compounds which can be used for treatment of osteoporosis or Paget's disease, for treatment of neurological and neuromuscular diseases and other nerve diseases or as psychotropic pharmaceuticals. The invention furthermore relates to a genetically modified non-human mammal, in which one or more chloride channels from the group consisting of CIC-3, CIC-4, CIC-6 and CIC-7 are not expressed or are expressed non-functionally, and somatic cell lines which are derived from such an animal, and the use thereof for the identification and testing of substances which are suitable for inhibiting chloride channels, in particular CIC-3, CIC-4, CIC-5, CIC-6 and/or CIC-7.--

#### **IN THE CLAIMS:**

Please cancel claims 1-25 and add the following new claims 26-41:

26. (New) A cell line which does not express or expresses to only a reduced extent one